Literature DB >> 6825222

Reflex chronotropic and inotropic effects of calcium channel-blocking agents in conscious dogs. Diltiazem, verapamil, and nifedipine compared.

H Nakaya, A Schwartz, R W Millard.   

Abstract

In chronically instrumented, conscious dogs, rapid injection of equihypotensive doses of three calcium channel-blocking agents, verapamil (250 micrograms/kg), diltiazem (200 micrograms/kg) and nifedipine (50 micrograms/kg), produced disparate chronotropic and inotropic responses. Although they all decreased mean arterial pressure by about 10%, heart rate (93 +/- 4 beats/min) was markedly increased to 175 +/- 12 with nifedipine, to 163 +/- 15 with verapamil, and only slightly increased to 118 +/- 7 with diltiazem. Contractile responses measured before (left ventricular dP/dtmax, 2749 +/- 131 mm Hg/sec) and during left ventricular ejection (endocardial dimension dD/dtmax, 57 +/- 4 mm/sec) were increased by 24% and 14% with nifedipine, decreased by 26% and 22% with verapamil, and were unchanged with diltiazem. These chronotropic and inotropic responses to rapid intravenous administration of the three drugs were increased in a dose-dependent manner. Similar results also were observed after slow infusion of these drugs. To determine the extent to which autonomic reflexes participated in these cardiac responses, propranolol (0.5 mg/kg) or propranolol plus atropine (0.1-0.2 mg/kg) was administered prior to injection of each calcium channel-blocking agent. Propranolol abolished the positive inotropic response to nifedipine and potentiated the negative inotropic response to verapamil. Positive chronotropic responses to verapamil, nifedipine, and diltiazem were attenuated by propranolol plus atropine. These results suggest that equihypotensive doses of the three prominent calcium channel-blocking agents exert different degrees of autonomic reflex activation in awake, unsedated dogs. These reflexes, which modulate the direct effects of calcium channel-blocking agents on chronotropic and inotropic variables of the heart, may have important clinical implications.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6825222     DOI: 10.1161/01.res.52.3.302

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  26 in total

1.  Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: a comparative study with nicorandil.

Authors:  L J van Woerkens; N R Baas; W J van der Giessen; P D Verdouw
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

2.  In-vitro study of the effect of clentiazem on rabbit aorta and on myocardium.

Authors:  H Narita; R Ginsburg
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 3.  Calcium-channel blockers and anaesthesia.

Authors:  P G Durand; J J Lehot; P Foëx
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

4.  The effects of intravenous nifedipine on cardiac hemodynamics and contractility in patients with coronary artery disease in the presence or absence of beta adrenergic blockade.

Authors:  O Visioli; R Bolognesi; F Cucchini; R Ferrari
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 5.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 6.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

7.  Attenuation by diltiazem of arterial baroreflex sensitivity in man.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; F Lhoste; C Richer; C Thuillez; A Jacolot
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  [Calcium antagonists in heart failure?].

Authors:  H Drexler; H Just
Journal:  Klin Wochenschr       Date:  1986-10-15

9.  Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.

Authors:  L Johannesen; J Vicente; J W Mason; C Erato; C Sanabria; K Waite-Labott; M Hong; J Lin; P Guo; A Mutlib; J Wang; W J Crumb; K Blinova; D Chan; J Stohlman; J Florian; M Ugander; N Stockbridge; D G Strauss
Journal:  Clin Pharmacol Ther       Date:  2015-11-28       Impact factor: 6.875

10.  Moderation of myocardial ischemia reperfusion injury by calcium channel and calmodulin receptor inhibition.

Authors:  Y Kimura; R M Engelman; J Rousou; J Flack; J Iyengar; D K Das
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.